Objective:To explore the clinical efficacy of aripiprazole and cerebral circulatory system therapy in pa-tients with schizophrenia(SP).Methods:A total of 116 SP patients who were admitted in the Second People's Hospital of Zhumadian from January 2022 to June 2023 were selected,and randomly divided into the observation group(58 ca-ses,aripiprazole and cerebral circulatory system therapy)and the control group(58 cases,aripiprazole).The clinical ef-ficacy,memory function,cognitive function,neurokines,and adverse reactions in both groups were compared.Results:The total effective rate of the observation group was higher than that of the control group,with statistical significance(P＜0.05).After treatment,the scores of wechsler memory scale(WMS),montreal cognitive assessment scale(MoCA),brain-derived neurotrophic factor(BDNF),nerve growth factor(NGF),neurotrophin-3(NT-3)and glial-derived neurotrophic factor(GDNF)all increased in the two groups,and the difference was statistically significant(P＜0.05).There was no signifi-cant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion:The combination of aripiprazole and cerebral circulatory system therapy treatment for SP patients can improve clinical efficacy,improve memory and cognitive function,regulate nerve factor levels,and have high safety.
关键词
精神分裂症/阿立哌唑/脑循环系统治疗仪/临床效果
Key words
schizophrenia/aripiprazole/cerebral circulatory system therapy/clinical effects
维普
万方数据